---
document_datetime: 2023-09-21 18:59:04
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/corlentor-epar-procedural-steps-taken-authorisation_en.pdf
document_name: corlentor-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4420208
conversion_datetime: 2025-12-17 14:47:45.675047
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Les Laboratoires SERVIER submitted on 16 April 2004 an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Corlentor, through the centralised procedure. After agreement by the CHMP on January 21 2004, this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993 as amended.

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Dr B. J. van Zwieten-Boot

Co-Rapporteur:   Dr. T. Kuitunen

## Scientific Advice:

The applicant received Scientific Advice from the CHMP on 24 March 1999. The Scientific Advice pertained to clinical aspects of the dossier.

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 16 April 2004.
- The Rapporteur's  first  Assessment  Report was  circulated  to  all  CHMP members  on  2  August 2004. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 19 July 2004.
- The procedure started on 17 May 2004.
- During the meeting on 13 - 16 September 2004, the CHMP agreed on the consolidated List of Questions  to  be  sent  to  the  applicant.  The  final  consolidated  List  of  Questions  was  sent  to  the applicant on 16 September 2004.
- The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  9 February 2005.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 18 March 2005.
- During  the  CHMP meeting on 18 - 21 April  2005  the  CHMP  agreed  on  a  list  of  outstanding issues  to  be  addressed  in  an  oral  explanation  and  in  writing  by  the  applicant.  The  list  of outstanding issues was sent to the applicant on 22 April 2005.
- The applicant submitted the written responses to the CHMP list of outstanding issues on 23 May 2005.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the list of outstanding issues to all CHMP members on 9 June 2005.
- During  the  CHMP  meeting  on  20  -  23  June  2005,  outstanding  issues  were  addressed  by  the applicant during an oral explanation before the CHMP on 22 June 2005.
- The Rapporteurs circulated the Updated Joint Assessment Report to all CHMP members on 11 July 2005.
- During the meeting on 25 - 27 July 2005, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation  to  Corlentor.  The  applicant  provided  the  letter  of  undertaking on  the Follow-Up Measures to be fulfilled post-authorisation on 26 July 2005.
- The  CHMP opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the European Commission, which adopted the corresponding Decisions on 25 October 2005.